June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Retinal Safety and Efficacy of a Dexamethasone Biodegradable Implant to Treat Macular Edema Associated to Retinal Vein Occlusion: A Phase I/II Clinical Trial
Author Affiliations & Notes
  • Rubens Siqueira
    Retina, Sao Paulo University, Sao Jose do Rio Preto, Brazil
  • Renato Cunha
    Retina, Sao Paulo University, Sao Jose do Rio Preto, Brazil
  • Andre Messias
    Retina, Sao Paulo University, Sao Jose do Rio Preto, Brazil
  • Armando Cunha
    Pharmacology, Minas Gerais Federal University, Belo Horizonte, Brazil
  • Silvia Fialho
    Pharmacology, Minas Gerais Federal University, Belo Horizonte, Brazil
  • Rodrigo Jorge
    Retina, Sao Paulo University, Sao Jose do Rio Preto, Brazil
  • Footnotes
    Commercial Relationships Rubens Siqueira, None; Renato Cunha, None; Andre Messias, None; Armando Cunha, None; Silvia Fialho, None; Rodrigo Jorge, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5066. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rubens Siqueira, Renato Cunha, Andre Messias, Armando Cunha, Silvia Fialho, Rodrigo Jorge; Retinal Safety and Efficacy of a Dexamethasone Biodegradable Implant to Treat Macular Edema Associated to Retinal Vein Occlusion: A Phase I/II Clinical Trial. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5066.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the safety and efficacy of a biodegradable implant containing 350 µg of dexamethasone (DDS-25 gauge) for the treatment of macular edema associated to retinal vein occlusion (vME)

Methods: Prospective, nonrandomized, open-label, phase I/II clinical trial, including 10 patients (n=10 eyes) with chronic vME, showing ETDRS best-correct visual acuity (BCVA) of 20/50 or worse. Evaluations included BCVA, spectral-domain optical coherence tomography (OCT - Spectralis Heidelberg Engineering) for determination of central macular thickness (CMT), full-field electroretinography (ISCEV standard ERG), kinetic visual field (Octopus 900), and fluorescein and indocyanine green angiography. Evaluations were performed at baseline, and 1, 4, 12 and 24 weeks after intravitreal DDS-25 insertion.

Results: The mean ± SE (range) CMT at baseline was 461.2 ± 41.3 μm (288 to 701 µm), and 439.6 ± 40.4 µm (259 to 631 µm), 442.5 ± 44.6 µm (255 to 632 µm), 354.6 ± 31.2 µm (228 to 537 µm), 316.5 ± 26.4 µm (226 to 441 µm) at 1, 4, 12, and 24 weeks respectively. Showing a significant improvement of 144.7 ± 46.0 µm at 24 weeks (P=0.0059; ANOVA). BCVA improved significantly in 0.14 ± 0.06 logMAR (7 ETDRS letters) at 24 weeks (P=0.0248), with 6 patients improving between 1 to 4 ETRS lines. Mean rod b-wave amplitude was 265.4 ± 30.4 µV at baseline and 255.6 ± 32.6 µV at 4 weeks (P=0.375), and no significant changes were observed for any ERG parameters, visual fields or angiography during follow-up. Related adverse events included no significant IOP elevation of 3.2 ± 1.6 mmHg (P=0.071) at week 24.

Conclusions: Our data suggests that the DDS-25 is safe and efficient for the treatment of vME in a short follow up time (6 months). A larger prospective randomized study is warranted to confirm these preliminary findings.

Keywords: 749 vascular occlusion/vascular occlusive disease • 487 corticosteroids • 763 vitreous  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×